Key result
Higher NT-proBNP, larger left atrium, and lower 6MWT distance predict ~39% long-term cardiovascular event rates in T2D.
Why the study?
This study aimed to identify baseline clinical, functional, and echocardiographic factors associated with long-term adverse cardiovascular events in middle-aged patients with type 2 diabetes with or without early symptoms of heart failure.
Are baseline NT-proBNP levels, left atrial size, and 6-minute walk test distance associated with long-term adverse cardiovascular events in middle-aged patients with type 2 diabetes?
Cohort (n=94)
Are baseline NT-proBNP levels, left atrial size, and 6-minute walk test distance associated with long-term adverse cardiovascular events in middle-aged patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
In middle-aged patients with type 2 diabetes, simple baseline assessments including NT-proBNP, left atrial size, and 6-minute walk distance help stratify long-term cardiovascular risk over nearly 9 years.
Aim. To identify factors associated with long-term adverse cardiovascular events (CVEs) in patients with type 2 diabetes (T2D). Material and methods. The study included 94 T2D patients aged 40 to 65 years with or without early symptoms of heart failure (HF). Patients underwent clinical and laboratory investigations, 6-minute walk test (6MWT), and echocardiography. Concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) was determined. After 8,8±0,72 years of follow-up, the prevalence of following CVEs among patients were assessed: any-cause death, myocardial infarction, stroke, emergency myocardial revascularization, hospitalization due to decompensated HF. We assessed the relationship between the development of long-term CVEs in T2D patients and the initial characteristics using logistic regression model. Results. Over a period of 8,8±0,72 years, CVEs occurred in 34 out of 88 (38,6%) patients with T2D. The baseline 6MWT values were lower in patients with CVEs (391,8±56,2 m vs 418,8±53,9 m, p=0,04). Stable coronary artery disease (55,9% vs 27,8%, p=0,008), early-stage HF (61,8% vs 27,8%; p=0,0016) were more common among patients with CVEs. Patients with CVEs had higher median initial NT-proBNP (46,9 pg/ml vs 24,2 pg/ml, p=0,01) and mean left atrial (LA) size (4,5±0,6 cm vs 4,19±0,5 cm, p=0,04) levels. The logistic regression established following factors associated with long-term CVEs in patients with T2D: NT-proBNP level (p=0,05), LA size (p=0,01), and 6MWT results (p=0,002). Conclusion. The development of long-term CVEs in middle-aged T2D patients with or without early-stage HF is associated with an initially increased NT-proBNP levels, an increase in left atrial size, and a decrease in 6MWT values. Further prospective studies with larger samples are needed to identify other factors affecting outcome in patients with early signs of HF.
No takes yet. Share an insight, caveat, or question.
Aa et al. (2021) conducted a cohort in Type 2 diabetes with or without early symptoms of heart failure (n=94). Baseline NT-proBNP level, left atrial size, and 6-minute walk test distance vs. Patients without long-term adverse cardiovascular events was evaluated on Long-term adverse cardiovascular events (any-cause death, myocardial infarction, stroke, emergency myocardial revascularization, or hospitalization due to decompensated heart failure) (p=0.002). Higher baseline NT-proBNP, larger left atrial size, and lower 6MWT distance were associated with long-term CVEs in T2D patients.
Synapse has enriched 10 related papers. Consider them for comparative context: